ImageneBio, Inc.
IMA · Biological Products, (No Diagnostic Substances) · 11.3M shares · +22%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: $663K (gross $663K)
Reference price $5.99 · est. market cap ~$68M — last insider purchase, 2025-12-24 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — clinical-stage biotech, very cash-rich.
Strengths
- Liquidity — current ratio 12.5 (88th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +22%/yr over 2y (dilution, book value/share -173%)
- Net lossNet loss (net margin -5668.6%)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Strong balance sheetStrong balance sheet — $135M cash & investments
- Revenue declineRevenue -100.0% YoY
- Notable holderHeld by 3 notable fund(s): CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, GOLDMAN SACHS GROUP INC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-6056.4%
Net margin
-5668.6%
Return on equity
-34.1%
Return on assets
-29.6%
ROIC
-28.7%
Revenue growth (QoQ)
-100.0%
Debt / equity
0.0×
Current ratio
12.5×
EBITDA
-$48M
Tangible book value
$133M
Cash & investments
$135M
Stock comp / revenue
1923.9%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-16 | Yarema Kristin | Grant | 85K | — |
| 2025-12-30 | Butler Erin | Grant | 22K | — |
| 2025-12-24 | SLATTERY JOSEPH P | Buy | 16K | $5.99 |
| 2025-07-28 | Marango Jotin | Tax withheld | 4.6K | $17.16 |
| 2025-07-28 | Marango Jotin | Grant | 16K | — |
| 2025-07-25 | Wang Stephen Hui | Grant | 13K | — |
| 2025-07-25 | Wang Jonathan Jian | Grant | 144K | — |
| 2025-07-25 | Wang Jonathan Jian | Grant | 971K | — |
| 2025-07-25 | Bonita David P | Option exercise | 379 | — |
| 2025-07-25 | Bonita David P | Buy | 84K | $29.90 |
| 2025-07-25 | Stampacchia Otello | Option exercise | 379 | — |
| 2025-07-25 | Stampacchia Otello | Buy | 268K | $29.90 |
| 2025-07-25 | ORBIMED ADVISORS LLC | Grant | 84K | $2.49 |
| 2025-07-25 | Butler Erin | Grant | 3.1K | — |
| 2025-07-25 | Wang Stephen Hui | Grant | 188K | — |
| 2025-07-25 | Wang Stephen Hui | Grant | 50K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-26 | Exec/director change | filing ↗ |
| 2026-06-17 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-04-13 | Material agreement3.02Exhibits | filing ↗ |
| 2026-03-17 | Exec/director change | filing ↗ |
| 2026-03-10 | ResultsExhibits | filing ↗ |
| 2026-02-17 | Exec/director change | filing ↗ |
| 2025-12-18 | Exec/director change | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-26 | 2026-06-22 | 0001193125-26-285424 ↗ |
| 8-K | 2026-06-17 | 2026-06-16 | 0001193125-26-274139 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001193125-26-211935 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-212073 ↗ |
| 8-K | 2026-04-13 | 2026-04-12 | 0001193125-26-151942 ↗ |
| 8-K | 2026-03-17 | 2026-03-12 | 0001193125-26-110945 ↗ |
| 8-K | 2026-03-10 | 2026-03-10 | 0001193125-26-099422 ↗ |
| 10-K | 2026-03-10 | 2025-12-31 | 0001193125-26-099434 ↗ |
| 8-K | 2026-02-17 | 2026-02-12 | 0001193125-26-054684 ↗ |
| 8-K | 2025-12-18 | 2025-12-12 | 0001193125-25-324798 ↗ |
| 8-K | 2025-11-19 | 2025-11-19 | 0001193125-25-286984 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001193125-25-275932 ↗ |